Table of Contents
In This Issue
In the Spotlight
- In the SpotlightRaghav Sundar and Patrick TanCancer Discov January 1 2018 8 (1) 14-16; DOI:10.1158/2159-8290.CD-17-1295
- In the SpotlightAlessandro Carugo and Giulio F. DraettaCancer Discov January 1 2018 8 (1) 17-19; DOI:10.1158/2159-8290.CD-17-1245
- In the SpotlightDavid F. SternCancer Discov January 1 2018 8 (1) 20-23; DOI:10.1158/2159-8290.CD-17-1243
Review
- ReviewAnastasios Stathis and Francesco BertoniCancer Discov January 1 2018 8 (1) 24-36; DOI:10.1158/2159-8290.CD-17-0605
Research Briefs
- Research Briefs | AuthorChoiceEirini Pectasides, Matthew D. Stachler, Sarah Derks, Yang Liu, Steven Maron, Mirazul Islam, Lindsay Alpert, Heewon Kwak, Hedy Kindler, Blase Polite, Manish R. Sharma, Kenisha Allen, Emily O'Day, Samantha Lomnicki, Melissa Maranto, Rajani Kanteti, Carrie Fitzpatrick, Christopher Weber, Namrata Setia, Shu-Yuan Xiao, John Hart, Rebecca J. Nagy, Kyoung-Mee Kim, Min-Gew Choi, Byung-Hoon Min, Katie S. Nason, Lea O'Keefe, Masayuki Watanabe, Hideo Baba, Rick Lanman, Agoston T. Agoston, David J. Oh, Andrew Dunford, Aaron R. Thorner, Matthew D. Ducar, Bruce M. Wollison, Haley A. Coleman, Yuan Ji, Mitchell C. Posner, Kevin Roggin, Kiran Turaga, Paul Chang, Kyle Hogarth, Uzma Siddiqui, Andres Gelrud, Gavin Ha, Samuel S. Freeman, Justin Rhoades, Sarah Reed, Greg Gydush, Denisse Rotem, Jon Davison, Yu Imamura, Viktor Adalsteinsson, Jeeyun Lee, Adam J. Bass and Daniel V. CatenacciCancer Discov January 1 2018 8 (1) 37-48; DOI:10.1158/2159-8290.CD-17-0395
Heterogeneity of actionable genomic alterations among primary and metastatic lesions suggests that biomarker profiling of a single primary tumor site may limit the success of targeted therapy in gastroesophageal adenocarcinoma.
- Research Briefs | AuthorChoiceYelena Y. Janjigian, Francisco Sanchez-Vega, Philip Jonsson, Walid K. Chatila, Jaclyn F. Hechtman, Geoffrey Y. Ku, Jamie C. Riches, Yaelle Tuvy, Ritika Kundra, Nancy Bouvier, Efsevia Vakiani, Jianjiong Gao, Zachary J. Heins, Benjamin E. Gross, David P. Kelsen, Liying Zhang, Vivian E. Strong, Mark Schattner, Hans Gerdes, Daniel G. Coit, Manjit Bains, Zsofia K. Stadler, Valerie W. Rusch, David R. Jones, Daniela Molena, Jinru Shia, Mark E. Robson, Marinela Capanu, Sumit Middha, Ahmet Zehir, David M. Hyman, Maurizio Scaltriti, Marc Ladanyi, Neal Rosen, David H. Ilson, Michael F. Berger, Laura Tang, Barry S. Taylor, David B. Solit and Nikolaus SchultzCancer Discov January 1 2018 8 (1) 49-58; DOI:10.1158/2159-8290.CD-17-0787
Prospective genomic profiling of patients with esophagogastric cancer identifies predictive biomarkers of sensitivity and resistance to trastuzumab and immune checkpoint inhibitors.
- Research BriefsMaria Rusan, Kapsok Li, Yvonne Li, Camilla L. Christensen, Brian J. Abraham, Nicholas Kwiatkowski, Kevin A. Buczkowski, Bruno Bockorny, Ting Chen, Shuai Li, Kevin Rhee, Haikuo Zhang, Wankun Chen, Hideki Terai, Tiffany Tavares, Alan L. Leggett, Tianxia Li, Yichen Wang, Tinghu Zhang, Tae-Jung Kim, Sook-Hee Hong, Neermala Poudel-Neupane, Michael Silkes, Tenny Mudianto, Li Tan, Takeshi Shimamura, Matthew Meyerson, Adam J. Bass, Hideo Watanabe, Nathanael S. Gray, Richard A. Young, Kwok-Kin Wong and Peter S. HammermanCancer Discov January 1 2018 8 (1) 59-73; DOI:10.1158/2159-8290.CD-17-0461
Blocking RNA polymerase II–mediated transcription with a CDK7/CDK12 inhibitor broadly enhances the efficacy of targeted therapies by suppressing transcriptional responses associated with establishment of a drug-tolerant state.
Research Articles
- Research Articles | AuthorChoiceAayoung Hong, Gatien Moriceau, Lu Sun, Shirley Lomeli, Marco Piva, Robert Damoiseaux, Sheri L. Holmen, Norman E. Sharpless, Willy Hugo and Roger S. LoCancer Discov January 1 2018 8 (1) 74-93; DOI:10.1158/2159-8290.CD-17-0682
Treatment discontinuation sensitizes MAPK inhibitor–resistant melanoma to PARP inhibition and augments a cell death–predominant drug-addiction phenotype.
- Research ArticlesXu Qian, Xinjian Li, Lin Tan, Jong-Ho Lee, Yan Xia, Qingsong Cai, Yanhua Zheng, Hongxia Wang, Philip L. Lorenzi and Zhimin LuCancer Discov January 1 2018 8 (1) 94-107; DOI:10.1158/2159-8290.CD-17-0712
Inhibition of phosphoribosyl pyrophosphate synthetase (PRPS) by AMPK under glucose-deprived or hypoxic conditions maintains homeostasis and promotes tumor cell survival.
- Research Articles | AuthorChoiceXiaoyang Zhang, Peter S. Choi, Joshua M. Francis, Galen F. Gao, Joshua D. Campbell, Aruna Ramachandran, Yoichiro Mitsuishi, Gavin Ha, Juliann Shih, Francisca Vazquez, Aviad Tsherniak, Alison M. Taylor, Jin Zhou, Zhong Wu, Ashton C. Berger, Marios Giannakis, William C. Hahn, Andrew D. Cherniack and Matthew MeyersonCancer Discov January 1 2018 8 (1) 108-125; DOI:10.1158/2159-8290.CD-17-0532
Varied noncoding and coding alterations observed across multiple cancer types converge to increase KLF5 activity and create a potential therapeutic vulnerability.
News in Brief
- News in BriefCancer Discov January 1 2018 8 (1) 4-4; DOI:10.1158/2159-8290.CD-NB2017-163
- News in BriefCancer Discov January 1 2018 8 (1) 4-5; DOI:10.1158/2159-8290.CD-NB2017-169
- News in BriefCancer Discov January 1 2018 8 (1) 5-6; DOI:10.1158/2159-8290.CD-NB2017-155
- News in BriefCancer Discov January 1 2018 8 (1) 6-6; DOI:10.1158/2159-8290.CD-NB2017-165
- News in BriefCancer Discov January 1 2018 8 (1) 6-7; DOI:10.1158/2159-8290.CD-NB2017-162
- News in BriefCancer Discov January 1 2018 8 (1) 7-7; DOI:10.1158/2159-8290.CD-NB2017-159
- News in BriefCancer Discov January 1 2018 8 (1) 8-8; DOI:10.1158/2159-8290.CD-NB2017-166
- News in BriefCancer Discov January 1 2018 8 (1) OF1-OF1; DOI:10.1158/2159-8290.CD-NB2017-170
- News in BriefCancer Discov January 1 2018 8 (1) OF2-OF2; DOI:10.1158/2159-8290.CD-NB2017-168
- News in BriefCancer Discov January 1 2018 8 (1) OF3-OF3; DOI:10.1158/2159-8290.CD-NB2017-167
- News in BriefCancer Discov January 1 2018 8 (1) OF4-OF4; DOI:10.1158/2159-8290.CD-NB2017-164
- News in BriefCancer Discov January 1 2018 8 (1) OF5-OF5; DOI:10.1158/2159-8290.CD-NB2017-152
- News in BriefCancer Discov January 1 2018 8 (1) OF6-OF6; DOI:10.1158/2159-8290.CD-NB2017-158
- News in BriefCancer Discov January 1 2018 8 (1) OF7-OF7; DOI:10.1158/2159-8290.CD-NB2017-156
- News in BriefCancer Discov January 1 2018 8 (1) OF8-OF8; DOI:10.1158/2159-8290.CD-NB2017-157
Research Watch
Clinical Trials
- Research WatchCancer Discov January 1 2018 8 (1) 9-9; DOI:10.1158/2159-8290.CD-RW2017-212
DNA Repair
- Research WatchCancer Discov January 1 2018 8 (1) 11-11; DOI:10.1158/2159-8290.CD-RW2017-228
Drug Resistance
- Research WatchCancer Discov January 1 2018 8 (1) OF9-OF9; DOI:10.1158/2159-8290.CD-RW2017-215
Epigenetics
- Research WatchCancer Discov January 1 2018 8 (1) 10-10; DOI:10.1158/2159-8290.CD-RW2017-229
Hepatocellular Carcinoma
- Research WatchCancer Discov January 1 2018 8 (1) 10-10; DOI:10.1158/2159-8290.CD-RW2017-221
- Research WatchCancer Discov January 1 2018 8 (1) OF10-OF10; DOI:10.1158/2159-8290.CD-RW2017-217
Immunology
- Research WatchCancer Discov January 1 2018 8 (1) 13-13; DOI:10.1158/2159-8290.CD-RW2017-232
- Research WatchCancer Discov January 1 2018 8 (1) OF11-OF11; DOI:10.1158/2159-8290.CD-RW2017-224
Immunotherapy
- Research WatchCancer Discov January 1 2018 8 (1) 12-12; DOI:10.1158/2159-8290.CD-RW2017-225
Leukemia
- Research WatchCancer Discov January 1 2018 8 (1) OF12-OF12; DOI:10.1158/2159-8290.CD-RW2017-216
Lung Cancer
- Research WatchCancer Discov January 1 2018 8 (1) OF13-OF13; DOI:10.1158/2159-8290.CD-RW2017-230
- Research WatchCancer Discov January 1 2018 8 (1) 12-12; DOI:10.1158/2159-8290.CD-RW2017-231
- Research WatchCancer Discov January 1 2018 8 (1) 9-9; DOI:10.1158/2159-8290.CD-RW2017-219
Lymphoma
- Research WatchCancer Discov January 1 2018 8 (1) 13-13; DOI:10.1158/2159-8290.CD-RW2017-220
- Research WatchCancer Discov January 1 2018 8 (1) OF14-OF14; DOI:10.1158/2159-8290.CD-RW2017-222
Mitosis
- Research WatchCancer Discov January 1 2018 8 (1) 11-11; DOI:10.1158/2159-8290.CD-RW2017-227
Multiple Myeloma
- Research WatchCancer Discov January 1 2018 8 (1) OF15-OF15; DOI:10.1158/2159-8290.CD-RW2017-218
Pancreatic Cancer
- Research WatchCancer Discov January 1 2018 8 (1) OF16-OF16; DOI:10.1158/2159-8290.CD-RW2017-223
Pediatric Cancers
- SignalingCancer Discov January 1 2018 8 (1) OF17-OF17; DOI:10.1158/2159-8290.CD-RW2017-213
Signaling
- Research WatchCancer Discov January 1 2018 8 (1) OF18-OF18; DOI:10.1158/2159-8290.CD-RW2017-226
- Research WatchCancer Discov January 1 2018 8 (1) OF19-OF19; DOI:10.1158/2159-8290.CD-RW2017-214
Targeted Therapy
- Research WatchCancer Discov January 1 2018 8 (1) OF20-OF20; DOI:10.1158/2159-8290.CD-RW2017-211
Volume 8, Issue 1
Jump to
